- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT04034810
Säkerhet och effekt av Silk Vista och Silk Vista Baby Flow Diverter för behandling av intrakraniell aneurysm (FIRST)
Säkerhet och effektivitet av Silk Vista och Silk Vista Baby Flow Diverter för behandling av intrakraniell aneurysm, en observationsstudie, prospektiv, enarms, internationell multicenterstudie.
The FIRST study is an observational, prospective, multi-center, international, single-arm, study. The aim of the study is to collect safety and efficacy information on the use of the silk vista and silk vista baby flow diverter in order to assess clinical safety and performance of the device for treating intracranial aneurysms.
All patients with intracranial aneurysm ruptured or unruptured, whatever the localization of the aneurysm, and treated with silk vista or silk vista baby, will be consecutively enrolled in the study.
The patient's inclusion and follow up in the study will occur as part of their usual standard of care.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Kontakter och platser
Studieorter
-
-
-
Liège, Belgien, 4000
- CHC Saint Joseph Liège
-
-
-
-
-
Bordeaux, Frankrike, 33000
- CHU de Bordeaux - Hôpital Pellegrin
-
Brest, Frankrike, 29200
- Hopital Cavale Blanche
-
Bron, Frankrike, 69677
- Hospices Civils de Lyon - Hôpital Neurologique
-
Caen, Frankrike, 14033
- CHU Caen, Radiologie interventionelle
-
Clermont-Ferrand, Frankrike, 63003
- Centre Hospitalier Universitaire Clermont Ferrand
-
Grenoble, Frankrike, 38043
- Centre Hospitalier Universitaire de Grenoble Alpes
-
Le Kremlin-Bicêtre, Frankrike, 94270
- Hôpital Kremlin Bicêtre
-
Limoges, Frankrike, 87000
- Chu Dupuytren Limoges
-
Marseille, Frankrike, 13009
- Hôpital Privé Clairval
-
Paris, Frankrike, 75651
- Pitié-Salpêtrière Hospital
-
Paris, Frankrike, 75019
- Fondation Rothschild
-
Rouen, Frankrike, 76000
- CHU Chalre Nicolle
-
Tours, Frankrike, 37044
- Centre Hospitalier Régional Universitaire de Tours
-
-
-
-
-
Jerusalem, Israel, 9112001
- Hadassah Medical Center
-
Nahariya, Israel, 22100
- Galilee Medical Center
-
-
-
-
-
Milan, Italien, 20162
- Niguarda Hospital
-
Monza, Italien, 20900
- San Gerardo Hospital
-
Treviso, Italien, 31100
- Cà Foncello Hospital
-
Udine, Italien, 33100
- Santa maria della misericordia hospital
-
-
-
-
-
Zagreb, Kroatien, 10000
- University Hospital Centre Zagreb
-
-
-
-
-
Nijmegen, Nederländerna, 6525 G
- Radboud University medical Center
-
-
-
-
-
Barakaldo, Spanien, 48903
- Hospital Universitario de cruces
-
Madrid, Spanien, 28222
- Hopsital universidad puerta de hierro
-
Madrid, Spanien, 28034
- Ramon y Cajal hospital
-
Oviedo, Spanien, 33011
- Unversitario Central de Asturias
-
Valladolid, Spanien, 47003
- Hospital Clinico Universitario de Valladolid
-
-
-
-
-
München, Tyskland, 81377
- Munich LMU University
-
-
-
-
-
Salzburg, Österrike, A-5020
- Universitätsklinik für Neurologie
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Patients with an intracranial aneurysm treated with silk vista and silk vista baby.
Beskrivning
Inclusion Criteria:
- Patient with intracranial aneurysms intended to be treated with the silk vista and silk vista baby (decision of use silk vista and silk vista baby is done independently and prior to the participation of the patient in the study)
- Patients with recanalized aneurysms previously treated with coils exclusively are also eligible.
- In case of multiple aneurysms, only treatment with silk vista and silk vista baby are allowed (between the initial index procedure to the 12 months follow up visit)
- Patient ≥ 18 years, who signed an informed consent.
Exclusion Criteria:
- Patient presenting with contra-indications to the use of silk vista and silk vista babyaccording to the IFU (Instruction for Use).
- Recanalized aneurysms initially treated with stent (including stent assisted coiling)
Studieplan
Hur är studien utformad?
Designdetaljer
- Observationsmodeller: COHORT
- Tidsperspektiv: PROSPECTIVE
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Morbi-mortality of silk vista and silk vista baby in the treatment of intracranial aneurysms.
Tidsram: At 12-months (-3 / + 6 months) post procedure
|
Characterized by the rate of the permanent neurologic deficits and procedure related mortality. |
At 12-months (-3 / + 6 months) post procedure
|
|
Morbi-mortality of silk vista and silk vista baby in the treatment of intracranial aneurysms.
Tidsram: At 12-months (-3 / + 6 months) post procedure
|
Characterized by the clinical outcome assessed by mRS of the permanent neurologic deficits and procedure related mortality. |
At 12-months (-3 / + 6 months) post procedure
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Safety of silk vista and silk vista baby
Tidsram: At T0
|
Assessed by the rate of adverse events |
At T0
|
|
Safety of silk vista and silk vista baby
Tidsram: At hospital discharge
|
Assessed by the rate of adverse events |
At hospital discharge
|
|
Safety of silk vista and silk vista baby
Tidsram: Up to 30 days (-10 / + 21 days) post- procedure.
|
Assessed by the rate of adverse events |
Up to 30 days (-10 / + 21 days) post- procedure.
|
|
Safety of silk vista and silk vista baby
Tidsram: At 6 months (-2/+3 months) post- procedure.
|
Assessed by the rate of adverse events |
At 6 months (-2/+3 months) post- procedure.
|
|
Safety of silk vista and silk vista baby
Tidsram: At 12 months (-3/+6 months) post- procedure.
|
Assessed by the rate of adverse events |
At 12 months (-3/+6 months) post- procedure.
|
|
Safety of silk vista and silk vista baby
Tidsram: At 3 years post procedure
|
Assessed by the rate of adverse events |
At 3 years post procedure
|
|
Safety of silk vista and silk vista baby
Tidsram: At 5 years post procedure
|
Assessed by the rate of adverse events |
At 5 years post procedure
|
|
Efficacy of silk vista and silk vista baby
Tidsram: At T0
|
Assessed by aneurysm occlusion rate |
At T0
|
|
Efficacy of silk vista and silk vista baby
Tidsram: At hospital discharge
|
Assessed by aneurysm occlusion rate |
At hospital discharge
|
|
Efficacy of silk vista and silk vista baby
Tidsram: Up to 30 days (-10 / + 21 days) post- procedure.
|
Assessed by aneurysm occlusion rate |
Up to 30 days (-10 / + 21 days) post- procedure.
|
|
Efficacy of silk vista and silk vista baby
Tidsram: Up to 6 months (-2/+3 months) post- procedure
|
Assessed by aneurysm occlusion rate |
Up to 6 months (-2/+3 months) post- procedure
|
|
Efficacy of silk vista and silk vista baby
Tidsram: Up to 12 months (-3 / + 6 months) post procedure
|
Assessed by aneurysm occlusion rate |
Up to 12 months (-3 / + 6 months) post procedure
|
|
Efficacy of silk vista and silk vista baby
Tidsram: Up to 3 years post procedure
|
Assessed by aneurysm occlusion rate |
Up to 3 years post procedure
|
|
Efficacy of silk vista and silk vista baby
Tidsram: Up to 5 years post procedure
|
Assessed by aneurysm occlusion rate |
Up to 5 years post procedure
|
|
Technical procedure
Tidsram: At T0
|
The practices related to the use of silk vista baby will be describe |
At T0
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Mario Martinez Galdamez, Dr, Hospital Clinico Universitario de Valladolid (HCUV), Spain
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- CIP 201802 SILK VISTA
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .